Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.6%

87 terminated/withdrawn out of 523 trials

Success Rate

75.8%

-10.7% vs industry average

Late-Stage Pipeline

8%

42 trials in Phase 3/4

Results Transparency

36%

98 of 273 completed trials have results

Key Signals

89 recruiting98 with results50 terminated37 withdrawn

Enrollment Performance

Analytics

N/A
276(63.6%)
Phase 2
55(12.7%)
Phase 1
37(8.5%)
Early Phase 1
24(5.5%)
Phase 4
23(5.3%)
Phase 3
19(4.4%)
434Total
N/A(276)
Phase 2(55)
Phase 1(37)
Early Phase 1(24)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (523)

Showing 20 of 523 trials
NCT06456242Not ApplicableCompleted

Contingency Management to Promote Smoking Cessation

Role: collaborator

NCT05074693Not ApplicableCompleted

Mobile Health and COVID-19

Role: collaborator

NCT06494150Phase 2Active Not Recruiting

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

Role: lead

NCT07217574Not ApplicableRecruiting

Program in Oncology for Tribal Health Systems.

Role: lead

NCT07631299Early Phase 1Not Yet Recruiting

Nebulized AER101 in Pre-op NSCLC

Role: lead

NCT04924322Phase 2Recruiting

Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies

Role: collaborator

NCT04741594Not ApplicableCompleted

Osseodensification and Implant Survival and Success

Role: lead

NCT03526432Phase 2Active Not Recruiting

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

Role: lead

NCT07622914Recruiting

The Role of Dietary Fiber in Mitigating Sarcopenia Risk in Head and Neck Cancer

Role: lead

NCT05523440Phase 2Terminated

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Role: lead

NCT07425119Not ApplicableNot Yet Recruiting

Project Q: Cue-based Treatment Intervention to Promote Cessation Among People Who Smoke Lightly or Non-daily

Role: collaborator

NCT05208671Not ApplicableCompleted

Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma

Role: lead

NCT06636214Not ApplicableNot Yet Recruiting

Adapting Changing Talk: Online (CHATO) to CHATO-Inclusive

Role: collaborator

NCT05275075Terminated

Identify microRNAs in Cachexia in Pancreatic Carcinoma

Role: lead

NCT05333978Not ApplicableTerminated

Optoacoustic Detection of Inflammation Using MSOT Device

Role: lead

NCT04930991Early Phase 1Terminated

High Dose Omeprazole in Patients With Pancreatic Cancer

Role: lead

NCT07491653Not ApplicableRecruiting

Fiber mHealth Intervention for Prediabetes

Role: lead

NCT05712395Not ApplicableRecruiting

The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease

Role: lead

NCT03890237Not ApplicableActive Not Recruiting

GAGE Act With Her-Ethiopia Evaluation

Role: collaborator

NCT03560050Not ApplicableCompleted

Technical Assistance for Child and Adult Care Food Program in Family Child Care Home

Role: lead